Theravance Rises on Report on Lung Drug: San Francisco Mover
This article is for subscribers only.
Theravance Inc. surged the most in a year after a staff report by U.S. regulators showed the once-daily lung disease treatment the company is developing with GlaxoSmithKline Plc may be able to win approval.
Theravance rose 19 percent to $28.36 at 4 p.m. New York time for its biggest gain since April 2012. The medication called Breo is meant to treat chronic obstructive pulmonary disease, an umbrella term for emphysema and chronic bronchitis.